FP7 Merlin

MERLIN is European Commission FP7-funded for research and technological development under grant agreement 602363. Tweets reflect the views of the project owner.

[FP7 Merlin @FP7Merlin]

MERLIN explores exciting new opportunities in stromal cell therapy R & D while making important contributions to the treatment of currently intractable inflammatory and immune-mediated liver diseases. https://t.co/vnFsYc1oov

[ADIPOA-2 @adipoa2]

Shout out to our dedicated followers! Our project has recently ended but please check out our follow on @EU_H2020 project @AutoCRAT2020 #osteoarthritis #Celltherapy #EVs #MSCs #Automation @HealthEuropa @eurireland

[AutoCRAT @AutoCRAT2020]

#MyFirstTweet! Greetings all! We are a @EU_H2020 research project! Please follow us if you are interested in #celltherapy, #automation, #cellmanufacturing and #osteoarthritis.

[FP7 Merlin @FP7Merlin]

Up to 56 patients are being recruited to take part in the @FP7Merlin trial, which will investigate the safety and efficacy of a new cellular #immunotherapy in patients with either Primary Sclerosing Cholangitis (#PSC) or Autoimmune Hepatitis (#AIH). https://t.co/zeniOL5bny

[LongerLifeFoundation @LongerLifeOrg]

Nonalcoholic fatty liver disease is the only liver disease with growing prevalence in the U.S. in the last 30 years. Epidemiologic research @Gut_BMJ reveals drivers: https://t.co/sf4LYV66m4

[NEPHSTROM @nephstrom]

JUST OUT! A new #OpenAccess @nephstrom publication in @FrontImmunol from our partners at @Istituto di Ricerche Farmacologiche @MarioNegriIRCCS https://t.co/xavxbrySI1 Congratulations to the team!

[EUPHORIA @EUPHORIAH2020]

Noninvasive modalities MRI, PET identify intestinal inflammation, longitudinally monitor disease status or detect changes in patients with #IBD. A paper assesses the applicability/utility of multispectral optoacoustic tomography #MSOT to evaluate #Colitis https://t.co/NqrVzNKZok

[NEPHSTROM @nephstrom]

Antibody treatment allows transplant of mismatched stem cells, tissues in mice https://t.co/jM7MjKYpWW

[EASLnews @EASLnews]

#EASL- @AASLDtweets Masterclass provides a unique educational collaboration of scientists from leading academic medical institutions from both sides of the Atlantic. https://t.co/Pol5mRK2Dq Deadline: 17 June
Join us in Amsterdam, Netherlands 05-07 December 2019

[Birmingham Health Partners @BHPComms]

Did you know it's #PatientParticipationWeek? There are plenty of opportunities for the public to get involved with BHP, and help influence and inspire the direction of our research. Our new Get Involved page shows how >> https://t.co/qwdekWNtru
#PPGWeek #BePartofResearch

[FP7 Merlin @FP7Merlin]

The @FP7Merlin #clinicaltrial: NOW RECRUITING

It is designed to:
i) Determine dose safety of ORBCEL-C (selected Mesenchymal stromal cells derived from human umbilical cord)
ii) Evaluate treatment activity through assessment of biomarkers
Read details https://t.co/r8AiMZQRnK

[FP7 Merlin @FP7Merlin]

The @FP7Merlin #clinicaltrial: NOW RECRUITING

It is designed to:
i) Determine dose safety of ORBCEL-C (selected Mesenchymal stromal cells derived from human umbilical cord)
ii) Evaluate treatment activity through assessment of biomarkers
Read details https://t.co/r8AiMZQRnK

[College of Medicine and Health (UoB) @unibirm_CMH]

Project MERLIN, a new trial coordinated by @CRCTU @ImmunologyUoB, is recruiting up to 56 patients to investigate the safety and efficacy of a new cell therapy for chronic #liverdisease: https://t.co/T6pVX9SRqz @NIHRBhamBRC @fp7merlin

[College of Medicine and Health (UoB) @unibirm_CMH]

A new cell therapy for chronic #liverdisease is being trialled as part of @fp7merlin by @CRCTU @ImmunologyUoB. It’s hoped that the trial could lead to a ground-breaking new way of treating people with Primary Sclerosing Cholangitis or Autoimmune Hepatitis: https://t.co/T6pVX9SRqz

[Tom Hemming Karlsen @tomhemmingk]

All good comes to an end. Thanks for the opportunity to serve the @EASLnews community, and congratulations and good luck to next Secretary General @phil_newsome7

[College of Medicine and Health (UoB) @unibirm_CMH]

Project MERLIN, a new trial coordinated by @CRCTU @ImmunologyUoB, is recruiting up to 56 patients to investigate the safety and efficacy of a new cell therapy for chronic #liverdisease: https://t.co/T6pVX9SRqz @NIHRBhamBRC @FP7Merlin

[NEPHSTROM @nephstrom]

The "International Journal of Molecular Sciences" (IF2017: 3.687) is dedicating a Special Issue to mesenchymal stem cells: "Novel MSC Perspectives: From Cell Regulation to Tissue Regeneration".
Details on the special issue here: https://t.co/5Fxnm6pzet
Deadline is 15 April 2019

[Birmingham Health Partners @BHPComms]

New treatment for chronic #liverdisease is on the horizon - researchers at @immunologyUoB & @uhbtrust are trialling the use of new #immunotherapy techniques, in partnership with @Orbsen Therapeutics >
https://t.co/iNYZ2wD6Yu
#whywedoresearch #iamresearch #cholangitis #hepatitis

[College of Medicine and Health (UoB) @unibirm_CMH]

.@unibirmingham has launched a trial, funded by @fp7merlin and @NIHRBhamBRC, that could lead to a ground-breaking new way of treating people with two types of chronic #liverdisease https://t.co/3Pk3tngJBg

[FP7 Merlin @FP7Merlin]

Up to 56 patients are being recruited to take part in the @FP7Merlin trial, which will investigate the safety and efficacy of a new cellular #immunotherapy in patients with either Primary Sclerosing Cholangitis (#PSC) or Autoimmune Hepatitis (#AIH). https://t.co/zeniOL5bny

[UniBirmingham News @news_ub]

A trial has been launched to test a new therapy for chronic #liverdisease @FP7Merlin @phil_newsome7 @unibirm_MDS https://t.co/mnFMxvGMVH… via @unibirmingham